No ice, no nut butter, no citrus
For patients who are not well-controlled on a treatment with metformin and basal insulin, a treatment intensification with a DPP-4 inhibitor may be feasible
What are the long-term considerations for patients who have lost over 100 pounds on tirzepatide (glucagon-like peptide-1 (GLP-1) and glucagon receptor agonist)?
If cost, supply shortages or side effects are driving the decision to stop, talking to a prescribing physician about alternatives is an important first step
At Meto, we work with patients on both these medications regularly, and the difference between an FDA-approved GLP-1 and an uncharacterized compounded peptide is not minor it is fundamental
If symptoms such as redness or slackness appear, pause for a week before resuming at a reduced frequency